Read original
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) will be participating in a partnered event with Svensk Galopp, at Jägersro on November 7, 2024. The Company’s diagnostic platform, LAMPlify®, will be introduced to a select group of invited trainers.
During the evening, Diagonal Bio will provide insights into recent test results from the collaboration with University of Copenhagen (UCPH). In addition, Diagonal Bio will showcase the functionality of LAMPlify® through a live demonstration, giving attendees a firsthand look at its capabilities and potential applications.
Approximately 70 trainers have been invited in collaboration with Svensk Galopp, where all will have the opportunity to learn more about LAMPlify® and how it could impact their field.
For additional information about, please contact:
Karin Wehlin, CEO
Phone: +46 703 052488
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio’s patented technology can also be used for the less regulated market segments via LAMPlify®.
